This article was published on April 22nd before the suspension, but new information that I learned I didn't know before. They are also working on test methods for Polio, Ebola, Bird Flu, and SARS. A HUGE potential.
Also Berman secured $13 million financing to grow his business without diluting the shareholders. Why would he incur debt to grow his business if he did not believe on the technology merits and to grow. Think about that. Why would he do this if he was looking to make a quick buck on COVID-19 throwing away 18 years of credible business? The more DD I do, the more comfort I get their business is legitimate, this suspension is likely without merit, and their explosive potential.
“Our screening method should allow for 80% of the suspected carriers of Coronavirus to exit the quarantine systems in the places where Coronavirus is rampant. However, we are not done with our Environs development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS,” Keith Berman, CEO of DECN commented.
In a bid to accelerate the development of the Covid-19 test kits, Decision Diagnostics has already secured a $13 million financing as part of a non-dilutive debt financing. The financing will go a long way in helping the company accelerate the purchasing of equipment for its Korean manufacturing facility. Part of the funds will be used to finance inventory as the company looks to embark on the commercialization of the much-needed Covid-19 test kits.
Market Data 
Markets 
